Ryan Scott

Patients with PSMA-positive metastatic castration-resistant prostate cancer in a phase 3 trial showed positive outcomes after receiving 177Lu-PSMA-I&T. Treatment with 177Lu-PSMA-I&T in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (CRPC) demonstrated meaningful benefits in radiographic progression-free survival […]

Subcutaneous Keytruda plus berahyaluronidase alfa meets phase 3 trial end points in non–small cell lung cancer. For patients with previously untreated metastatic non–small cell lung cancer (NSCLC), treatment with Keytruda (pembrolizumab) plus berahyaluronidase alfa (subcutaneous Keytruda; MK-3475A) in combination with

The FDA has approved an updated drug labeling for Sandoz’s fludarabine phosphate injection in the treatment of B-cell CLL as part of the Oncology Center of Excellence’s Project Renewal initiative. The Food and Drug Administration (FDA) has approved updated drug

The FDA will be reviewing an application submitted to seek an accelerated approval of Dato-DXd for patients with EGFR-mutated NSCLC. A new biologics license application (BLA) has been submitted to the Food and Drug Administration (FDA) seeking the accelerated approval

The Food and Drug Administration (FDA) issued a “Study May Proceed” letter, allowing a phase 3 trial to evaluate first-line treatment with amezalpat (TPST-1120) in combination with the current standard of care, Tecentriq (atezolizumab) and Avastin (bevacizumab), versus standard of

The FDA has approved MI Cancer Seek, a companion diagnostic test that uses whole exome and transcriptome sequencing to identify patients with cancer who may benefit from targeted therapies. MI Cancer Seek™ has received approval from the Food and Drug

Using post-transplant cyclophosphamide (PTCY) for graft-versus-host disease prophylaxis in patients with myelodysplastic syndromes is a valid option compared to antithymocyte globulin (ATG). Graft-versus-host disease (GVHD) prophylaxis using posttransplant cyclophosphamide (PTCY) remains a valid option for patients with myelodysplastic syndromes (MDS)

Tranexamic Acid During Radical Cystectomy Does Not Lead to Blood Transfusion Reduction in Bladder Cancer The use of prophylactic tranexamic acid did not lead to a reduction in blood transfusion for patients undergoing open radical cystectomy for their bladder cancer.

ONCT-534, a dual-action AR inhibitor, showed a well-tolerated safety profile and potential clinical benefits in patients with relapsed/refractory mCRPC. Treatment with the investigational, dual-action androgen receptor (AR) inhibitor, ONCT-534, elicited a well-tolerated safety profile when given to patients with relapsed/refractory

FDA Accepts New Drug Application for UGN-102 in Bladder Cancer A new drug application (NDA) has been accepted by the Food and Drug Administration (FDA) for the intravesical solution of UGN-102 (mitomycin) in the treatment of low-grade intermediate-risk non-muscle-invasive bladder